# Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

> **NCT00031902** · PHASE1 · UNKNOWN · sponsor: **Lymphoma Trials Office**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** bleomycin sulfate
- **BIOLOGICAL:** rituximab
- **DRUG:** prednisolone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00031902
- **Lead sponsor:** Lymphoma Trials Office
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00031902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00031902, "Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00031902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*